Neuroendocrine effects of electroconvulsive therapy (ECT)

Psychopharmacology Bulletin

Volumn 33, Issue 2, 1997, Pages 265-271

  Swartz, Conrad M ^a,b  

^a East Tennessee State University   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cortisol; Depression; Electroconvulsive therapy; Hormones; Prolactin

Indexed keywords

BLOOD SAMPLING; BRAIN FUNCTION; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; ILLNESS BEHAVIOR; NEUROENDOCRINE SYSTEM; PREDICTION; PRIORITY JOURNAL; PROLACTIN RELEASE; RADIOIMMUNOASSAY; REVIEW;

ANTIPSYCHOTIC AGENTS; DEXAMETHASONE; ELECTROCONVULSIVE THERAPY; HUMANS; HYDROCORTISONE; NEUROSECRETORY SYSTEMS; OXYTOCIN; PROLACTIN;

EID: 0030787556     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Abrams, R, and Swartz, CM. Electroconvulsive therapy and prolactin release: Effect of stimulus parameters. Convulsive Ther. 1:115-119, 1985.
2. Albala, AA; Greden, JF; Tarika, J; and Carroll, BJ. Changes in serial dexamethasone suppression tests among unipolar depressives receiving electroconvulsive treatment. Biol. Psychiatry 16:551-560, 1981.
3. Arato, M; Erdos, A; Kurcz, M; Vermes, I; and Fekete, M. Studies on the prolactin response induced by electroconvulsive therapy in schizophrenics. Acta Psychiatr. Scand. 61:239-244, 1980.
4. Asnis, GM; Harkavy Friedman, JM; Miller, AH; Iqbal, N; Lo, ES; Cooper, TB; Halbreich, U; Lemus, CZ; van Praag, HM; and Rubinson, E. Plasma dexamethasone and cortisol levels in depressed outpatients. J. Affect. Disord. 16:5-10, 1989.
5. Berson, SA, and Yalow, RS. Radioimmunoassay of ACTH in plasma. J. Clin. Invest. 47:2725-2751, 1968.
6. Chadio, SE, and Antoni, FA. Specific oxytocin agonist stimulates prolactin release but has no effect on inositol phosphate accumulation in isolated rat anterior pituitary cells. J. Mol. Endocrinol. 10:107-112, 1993.
7. Coffey, CE; Lucke, J; Weiner, RD; Krystal, AD; and Aque, M. Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT. Biol. Psychiatry 37:777-788, 1995.
8. Coffey, CE; Wilkinson, WE; Weiner, RD; Ritchie, JC; and Aque, M. The dexamethasone suppression test and quantitative cerebral anatomy in depression. Biol. Psychiatry 33:442-449, 1993.
9. Coryell, W. Are serial dexamethasone suppression tests useful in electroconvulsive therapy? J. Affect. Disord. 10:59-66, 1986.
10. Coryell, W, and Zimmerman, M. The dexamethasone suppression test and ECT outcome: A six month followup. Biol. Psychiatry 18:21-27, 1983.
11. Cosgriff, JP; Abbott, RM; Oakley-Browne, MA; and Joyce, PR. Cortisol hypersecretion predicts early depressive relapse after recovery with electroconvulsive therapy. Biol. Psychiatry 28:1007-1010, 1990.
12. Dana-Haeri, J; Trimble, MR; and Oxley, J. Prolactin and gonadotropin changes following generalized and partial seizures. J. Neurol. Neurosurg. Psychiatry 46:331-335, 1983.
13. Deakin, JWF; Ferrier, IN; Crow, TJ; Johnstone, EC; and Lawler, P. Effects of ECT on pituitary hormone release: Relationship to seizure, clinical variables, and outcome. Br. J. Psychiatry 143:618-624, 1983.
14. Decina, P; Sackeim, HA; and Malitz, S. Prognostic value of serial dexamethasone suppression tests during and following ECT. Psychopharmacol. Bull. 19:85-87, 1983.
15. Devanand, DP; Decina, P; Sackeim, HA; Hopkins, N; Novacenko, H; and Malitz, S. Serial dexamethasone suppression tests in initial suppressors and nonsuppressors treated with electroconvulsive therapy. Biol. Psychiatry 22:463-472, 1987.
16. Drago, F; Mauceri, F; Fidilio, M; Cavaliere, S; Pulvirenti, L; and Foti, F. Effects of thyrotropin-releasing hormone, oxytocin, and prolactin on thiopenthal-induced narcosis in rats. Brain Res. Bull. 28:781-783, 1992.
17. Drevets, WC; Videen, TO; Price, JL; and Preskorn, SH. A functional anatomical study of unipolar depression. J. Neurosci. 12:3628-3641, 1992.
18. Fink, M; Gujavarty, K; and Greenberg, L. Serial dexamethasone suppression tests and clinical outcome in ECT. Convulsive Ther. 3:111-120, 1987.
19. Ghosh, R, and Sladek, CK. Prolactin modulates oxytocin mRNA during lactation by its action on the hypothalamo-neurohypophyseal axis. Brain Res. 672:24-28, 1995.
20. Gold, PW, and Chrousos, GP. Clinical studies with corticotropin releasing factor: Implications for the diagnosis and pathophysiology of depression, Cushing's disease, and adrenal insufficiency. Psychoneuroendocrinology 10:401-419, 1985.
21. Greden, JF; Albala, AA; Haskett, RF; James, NM; Goodman, L; Steiner, M; and Carroll, BJ. Normalization of the dexamethasone suppression test: A laboratory index of recovery from endogenous depression. Biol Psychiatry 15:449-458, 1980.
22. Griswold, RL. Plasma adrenaline and noradrenaline in electroshock therapy in man and rats. J. Appl. Physiol. 12:117-120, 1958.
23. Grunhaus, L; Tiongco, D; Pande, A; Eiser, A; Haskett, RF; Greden, JF; and Shipley, JE. Monitoring of antidepressant response to ECT with polysomnographic recording and the dexamethasone suppression test. Psychiatry Res. 24:117-185, 1988.
24. Grunhaus, L; Zelnick, T; Albala, AA; Haskett, RF; Zis, A; and Greden, JF. Serial DSTs in patients treated with ECT only. J. Affect. Disord. 13:233-240, 1987.
25. Hoppener, RJE; Rentmeester, TH; Amoldussen, W; Hulsman, J; and Meijers, CAM. The changes in serum prolactin level following partial and generalized seizures. Br. J. Clin. Pract. Suppl. 18:193-195, 1982.
26. Katona, CLE; Aldridge, CR; Roth, M; and Hyde, J. The dexamethasone suppression test and prediction of outcome in patients receiving ECT. Br. J. Psychiatry 150:315-318, 1987.
27. Lipman, RS; Backup, C; Bobrin, Y; Delaplane, JM; Doeff, J; Gittleman, S; Joseph, R; and Kanefield, M. Dexamethasone suppression test as a predictor of response to electroconvulsive therapy. I: Inpatient treatment. Convulsive Ther. 2:151-160, 1986a.
28. Lipman, RS; Uffner, W; Schwalb, N; Ravetz, R; Lief, B; Levy, S; and Levenberg, D. Dexamethasone suppression test as a predictor of response to electroconvulsive therapy. II: Six-month follow-up. Convulsive Ther. 2:161-168, 1986b.
29. Lowy, MT, and Meltzer, HY. Dexamethasone bioavailability: Implications for DST research. Biol. Psychiatry 22:373-385, 1987.
30. Ohman, R; Walinder, J; Balldin, J; Wallin, L; and Abrahamsson, L. Prolactin response to electroconvulsive therapy. Lancet 2:936-938, 1976.
31. O'Sullivan, BT; Hunt, GE; Johnson, GF; and Caterson, ID. The plasma dexamethasone window: Evidence supporting its usefulness to validate dexamethasone suppression test results. Biol. Psychiatry 25:739-754, 1989.
32. Palmer, RL; Mani, C; Abdel-Kariem, MAA; and Brandon, S. Dexamethasone suppression tests in the context of a double-blind trial of electroconvulsive therapy and simulated ECT. Convulsive Ther. 6:13-18, 1990.
33. Parra, A; Velasco, M; Cervantes, C; Munoz, H; Cerbon, M; Velasco, F. Plasma prolactin increase following electric stimulation of the amygdala in humans. Neuroendocrinology 31:60-65, 1980.
34. Pina-Cabral, JM, and Rodrigues, C. Blood catecholamine levels, factor VIII and fibrinolysis after electroshock. Br. J. Hematol. 28:371-380, 1974.
35. Redke, F; Bjorkman, S; and Rosberg, B. Pharmacokinetics and clinical experience of 20-h infusions of methohexitone in intensive care patients with postoperative pyrexia. Br. J. Anaesthes. 66:53-59, 1991.
36. Ritchie, JC; Belkin, BM; Krishnan, RR; Nemeroff, CB; and Carroll, BJ. Plasma dexamethasone concentrations and the dexamethasone suppression test. Biol. Psychiatry 27:159-173, 1990.
37. Robin, A; Binnie, CD; and Copas, JB. Electrophysiological and hormonal responses to three types of electroconvulsive therapy. Br. J. Psychiatry 147:707-712, 1985.
38. Rudorfer, MV; Risby, ED; Osman, OT; Gold, PW; and Potter, WZ. Hypothalamic-pituitary-adrenal axis and monoamine transmitter activity in depression: A pilot study of central and peripheral effects of electroconvulsive therapy. Biol. Psychiatry 29:253-264, 1991.
39. Scott, AI; Shering, PA; Lightman, SL; and Legros, JJ. The release of oxytocin, vasopressin and associated neurophysins after electroconvulsive therapy. Human Psychopharmacol. 6:161-164, 1991.
40. Scott, AI; Whalley, LJ; Bennie, J; and Bowler, G. Oestrogen-stimulated neurophysin and outcome after electroconvulsive therapy. Lancet 1(8495):1411-1414, 1986.
41. Scott, AI; Whalley, LJ; and Legros, JJ. Treatment outcome, seizure duration, and the neurophysin response to ECT. Biol. Psychiatry 25:585-597, 1989.
42. Smith, J; Williams, K; Birkett, S; Nicholson, H; Glue, P; and Nutt, DJ. Neuroendocrine and clinical effects of electroconvulsive therapy and their relationship to treatment outcome. Psychol. Med. 24:547-555, 1994.
43. Sperling, MR; Pritchard, PB; Engel, J; Daniel, C; Sagel, J. Limbic seizures and prolactin. Epilepsia 26:529, 1985.
44. Swartz, CM. The time course of post-ECT prolactin levels. Convulsive Ther. 1:81-89, 1985a.
45. Swartz, CM. Characterization of the total amount of prolactin released by electroconvulsive therapy. Convulsive Ther. 1:252-257, 1985b.
46. Swartz, CM. Anomalous patterns of ECT-induced hormone release. Convulsive Ther. 5:185-189, 1989.
47. Swartz, CM. ECT emergence agitation and succinylcholine dose. J. Nerv. Ment. Dis. 178:455-457, 1990.
48. Swartz, CM. Quantity of prolactin released by ECT seizure Convulsive Ther. 7:62, 1991a.
49. Swartz, CM. ECT-induced prolactin release as an epiphenomenon. Convulsive Ther. 7:85-91, 1991b.
50. Swartz, CM. Electroconvulsive therapy-induced cortisol release after dexamethasone in depression. Neuropsychobiology 25:130-133, 1992.
51. Swartz, CM. Anesthesia for ECT. Convulsive Ther. 9:301-316, 1993.
52. Swartz, CM, and Abrams, R. Prolactin levels after bilateral and unilateral ECT. Br. J. Psychiatry 144:643-645, 1984.
53. Swartz, CM, and Chen, JJ. ECT-induced cortisol release: Changes with depressive state. Convulsive Ther. 1:15-21, 1985.
54. Swartz, CM, and Saheba, NC. Dose effect on dexamethasone suppression testing with ECT. Ann. Clin. Psychiatry 2:183-188, 1990.
55. Swartz, CM; Wahby, VS; and Vacha, R. Characterization of the pituitary response in the TRH test by kinetic modeling. Acta Endocrinol. 112:43-48, 1986.
56. Trimble, MR. Serum prolactin in epilepsy and hysteria. Br. Med. J. 2:1682, 1978.
57. Uvnas, MK; Alster, P; Hillegaart, V; and Ahlenius, S. Suggestive evidence for a DA D3 receptor-mediated increase in the release of oxytocin in the male rat. Neuroreport 6:1338-1340, 1995.
58. Vigas, M; Stowasserova, N; Nemeth, S; and Jurcovicova, J. Effect of electroconvulsive therapy without anticonvulsive premedication on serum growth hormone in man. Horm. Res. 6:65-60, 1975.
59. Walker, WR, and Swartz, CM. ECT during high-risk pregnancy. Gen. Hosp. Psychiatry 16:348-353, 1994.
60. Widerlov, E; Ekman, R; Jensen, L; Borglund, L; and Nyman, K. Arginine vasopressin, but not corticotropin releasing factor, is a potent stimulator of adrenocorticotropic hormone following electroconvulsive treatment. J. Neural Transm. 75:101-109, 1989.
61. Yerevanian, BI; Olafsdottir, H; Milanese, E; Russotto, J; Mallon, P; Baciewicz, G; and Sagi, E. Normalization of the dexamethasone suppression test at discharge from the hospital: Its prognostic value. J. Affect. Disord. 5:191-197, 1983.
62. Zis, AP; Yatham, LN; Lam, RW; Clark, CM; Srisurapanont, M; and McGarvey, K. Effect of stimulus intensity on prolactin and cortisol induced by unilateral electroconvulsive therapy. Neuropsychopharmacology 15:263-270, 1996.